On the cusp of change: New therapeutic modalities for HCV
Journal Title: Annals of Hepatology - Year 2010, Vol 9, Issue 0
Abstract
We are at the cusp of significant new alternatives for the treatment of chronic hepatitis C. Among more than 100 drugs in development, some are ready to be approved and in the market as soon as next year. The protease inhibitors Telaprevir and Boceprevir, will change the SOC treatment to triple therapy, (combined with peg IFN and RBV), with duration of treatment guided by rapid virological response. In this article we present the data supporting the approval of Telaprevir and Boceprevir, and information on polymerase inhibitors and IFN free proof of concept trials. Finally we discuss which patients should wait for DAA based therapies and which should be considered for peg IFN/RBV now. In the next 5 years our patients can expect higher response rates and truncated duration of therapy. They can expect drug cocktails or combos but for the next years these novel drugs will still require peg IFN and RBV. Also, a new era of resistance as a barrier to therapy will require sub typing and more viral monitoring. Overall, improved outcomes will come at the expense of more adverse events and increased costs of treatment.
Authors and Affiliations
Maribel Rodríguez-Torres
Keywords
Related Articles
- EP ID EP77976
- DOI -
- Views 136
- Downloads 0
Short- and Long-term Outcomes between Young and Older HCC Patients Exceeding The Milan Criteria after Hepatectomy
Aim. The objective of this study was to evaluate short- and long-term survival after surgical treatment between young and older hepatocellular carcinoma (HCC) patients beyond the Milan criteria. Material and methods. One...
Virological techniques for the diagnosis and monitoring of hepatitis B and C.
Liver fibrosis in bile duct-ligated rats correlates with increased hepatic IL-17 and TGF-β2 expression
Background and rationale for the study. IL-17, TGF-β1/2 are cytokines involved in the development of kidney, pulmonaryand liver fibrosis. However, their expression kinetics in the pathogenesis of cholestatic liver fibro...
Effects of combined genes of CTLA4Ig and IDO in post-liver transplantation immune tolerance of rats
Background and rationale for the study. Previous studies showed that CTLA4Ig and indoleamine 2,3-dioxygenase (IDO) genes played regulatory role in organ transplantation but failed to reach satisfactory effects. In this...
Inflammatory myofibroblastic tumor of the liver
Hepatic inflammatory myofibroblastic tumors are uncommon low grade malignant neoplasms. They can be confused clinically and by imaging studies with abscess.